Cervical Cancers Treatment Guideline KMHK
|
|
- Marion Carroll
- 5 years ago
- Views:
Transcription
1 Cervical Cancers Treatment Guideline KMHK
2 子宮頸癌修訂紀錄 修訂日期修訂內容摘要 修訂頁次 版本 97 年 98 年 99 年 100 年 101 年 102 年 103 年 104 年 子宮頸癌診療指引新制訂新增子宮頸篩檢凖則多科會議討論檢視後未修改多科會議討論檢視後未修改多科會議討論檢視後未修改多科會議討論檢視後未修改 ;stage Ia1 做 simple Hysterectomy 或 Conization;stage Ia2 以上評估是否可開刀做 radical hysterectomy 且要評估 lymph node 情形, 決定是否要做化療及放射線治療 多科會議討論檢視後未修改多科會議討論檢視後未修改 E3~
3 Cervical Cancer 子宮頸癌治療準則 E-1 STAGING TREATMENT Completed Simple Hysterectomy Stage IA Stage IA1 (Microinvasive) Childbearing t completed Conization + Surveillance Stage IA2 Operability RH + PLND Pelvic RT+Brachytherapy Stage IB Tumor size Histology (Biopsy) paraaortic nodes (MRI or CT or PET) Stage IB1 < 4 cm Squamous cell ca Adeno ca. Small cell ca. Stage IB2 > 4 cm enlarged paraaortic LN or pelvic LN Operability Operability Preop CCRT Cisplatin + 5 FU Good response Poor response Pelvic+RT +Brachytherapy RH + PLND CCRT(Cisplatincontaining RH + PLND Histology(surgical specimen) Tumor size > 4cm LVI (+) Deep stromal invasion Lymph node (+) Positive margin Parametrial invasion RH + PLND Completed RT + chemotherapy Surveillance Pelvic or paraaortic RT+chemotherapy
4 Cervical Cancer 子宮頸癌治療準則 E-2 STAGING Stage II A1, II A2 Operability TREATMENT RH + PLND Concurrent chemotherapy and radiation Histology(surgical specimen) Tumor size >4cm LVI(+) Deep stromal invasion Lymph node(+) Positive margin Parametrial invasion Surveillance Pelvic or Paraaortic RT + chemotherapy Stage IIB, III, IVA Concurrent chemotherapy and radiation (pelvic or paraaortic) Stage IVB Palliation (chemotherapy or / and radiation) Chemotherapy, palliation Recurrent Ca.. with Distant intra-abdominal or paraaortic metastases Prior treatment Pelvic RT Central Side wall Pelvic exenteration RT or Chemotherapy Completed RT ± Chemotherapy
5 Cervical Screening 子宮頸篩檢準則 FINDINGS ON COLPOSCOPY INITIAL FINDINGS SCREENING/ PAPTEST CERVICAL BIOPSY FINDINGS rmal Repeat Pap test at 6 mo Repeat Pap test every 6 mo E-3 FOLLOW-UP TREATMENT If LSIL persists for 24 mo,consider treatment If returns to normal, Pap test every 12 mo If Pap test indicates HSIL Colposcopy I CKC or LEEP or Cryotherapy or Laser Satisfactory colposcopy Cervical biopsy II Microinvasive CKC or LEEP or Cryotherapy or Laser or Total hysterectomy NCCN Cervical Cancer Treatment Guidelines Invasive NCCN Cervical Cancer Treatment Guidelines LSIL/ASCUS Cervical intraepithelial neoplasia (CIN) I ECC FINDINGS Positive Positive I or III I or III CKC or LEEP CKC or LEEP Unsatisfactory colposcopy Cervical biopsy +ECC I Positive I or III CKC or LEEP CKC or LEEP or Cryotherapy or Laser CKC=Cold-knife conization ECC=Endocervical curretage LEEP=Loop electrosurgical excision procedure II Cancer Positive I or III CKC or LEEP or Total hysterectomy after CKC or LEEP for definitive diagnosis CKC or LEEP or Cryotherapy or Laser or Total hysterectomy KMU Cervical Cancer Treatment Guidelines
6 Cervical Screening 子宮頸篩檢準則 E-4 FINDINGS ON INITIAL SCREENING/ PAPTEST COLPOSCOPY FINDINGS CERVICAL BIOPSY FINDINGS rmal Review screening Pap test FOLLOW-UP If high grade, consider LEEP for definitive TREATMENT If LSIL persists for 24 mo,consider treatment Repeat Pap test every 6 mo If returns to normal,pap test every 12 mo If Pap test indicates HSIL Colposcopy I CKC or LEEP or Cryotherapy or Laser Satisfactory colposcopy Cervical biopsy II CKC or LEEP or Cryotherapy or Laser or Consider Total hysterectomy Microinvasive NCCN Cervical Cancer Treatment Guidelines Invasive ECC FINDINGS NCCN Cervical Cancer Treatment Guidelines HSIL Positive for dysplasia CKC or LEEP Positive for dysplasia, II, III) CKC or LEEP Unsatisfactory colposcopy Cervical biopsy +ECC I Positive for dysplasia, II, III) CKC or LEEP CKC or LEEP or Cryotherapy or Laser CKC=Cold-knife conization ECC=Endocervical curretage LEEP=Loop electrosurgical excision procedure II Cancer Positive for dysplasia, II, III) CKC or LEEP or Total hysterectomy after CKC or LEEP for definitive diagnosis CKC or LEEP or Cryotherapy or Laser or Total hysterectomy KMU Cervical Cancer Treatment Guidelines
7 Cervical Screening 子宮頸篩檢準則 E-5 FINDINGS ATTREATMENT FOLLOW-UP POST-TREATMENT After CKC or LEEP for CIN margins or margin status unknown Cryotherapy Laser rmal (no dysplasia) I II Margin Pap test at 6 mo mo Pap test at 6 mo Pap test at 6 mo Pap test at 6 mo Pap test at 6 mo Consider ECC (category 2B) rmal ASCUS LSIL HSIL Resume annual PAP testing Repeat Pap test at 6 mo Repeat Pap test at 6 mo Repeat Pap test at 6 mo Consider colposcopy Colposcopy ASCUS LSIL HSIL Resume annual PAP testing Repeat Pap test at 6 mo Repeat Pap test at 6 mo Consider colposcopy Colposcopy Positive margins Margin I,III Pap test at 6 mo Consider ECC (category 2B) ASCUS HSIL LSIL Colposcopy or Total hysterectomy Resume annual PAP testing
8 Cervical Screening 子宮頸篩檢準則 E-6 FOLLOW-UP OF CERVICAL BIOPSY/ENDOMETRIAL BIOPSY FINDINGS FOLLOW-UP further evaluation of endometrium Endometrial biopsy Hyperplasia Atypical hyperplasia Consider dilatation and Curettage(D&C) D&C,II III See E7 for Follow-up of CKC AGCUS AGCUS with endometrial cells or Favor endometrial cells or Age > 40yr or Endometrial cancer risk factors f Colposcopy ECC and endometrial biopsy ECC Cancer ndiagnostic rmal, II, III KMU Endometrial Cancer Treatment Guidelines Consider repeat depending on ECC/ cervical biopsy findings or consider transvaginal ultrasound for metrial endo stripe thickness Individualized follow-up based on review of AGCUS smear CKC If CKC Adenocarcinoma in situ/ glandular intraepitheli al neoplasia Consider referral to gynecologic oncologist margins margins, fertility desired Hysterectomy (standard preferred) Pap test with ECC at 6 mo Requires consent / counseling Recommend hysterectomy when childbearing completed AGCUS favor cervical neoplasia Colposcopy ECC f Endometrial Cancer Risk Factors:Obesity,estrogen replacement therapy,polycystic ovarian disease, tamoxifen,anovulation Cervical biopsy Adenocarcinoma in situ Cancer rmal Adenocarcinoma in situ I, III (squamous) CKC KMU Endometrial/Cervical Cancer Treatment Guidelines Individualized follow-up based on review of AGCUS smear CKC Repeat Pap test at 6 mo if ECC negative CKC Cancer KMU Cervical Cancer Treatment Guidelines Positive margins Total hysterectomy or Repeat CKC at 3 mo If fertility desired, consent / counseling required Recommend hysterectomy when childbearing completed
9 Endometrial cancer Treatment Guideline KMHK
10 子宮頸癌修訂紀錄修訂日期修訂內容摘要修訂頁次版本 104 年子宮內膜癌診療指引新制訂 E7~10 1.0
11 Endometrial cancer 子宮內膜癌治療準則 E7 Medically Primary (+)for Surgical radiation staging operable Primary surgery Endomctrial (+) for cancer (-) for Hysteroscopel (-) for cancer Follow-up G1 G2 G3 Completely surgical staging:.ath+bso Stage Adverse risk(-) Adverse risk(+) observe Brachytherapy and/or pelvic RT Brachytherapy and/or pelvic RT.Cytology.Pelvic lymphadenectomy.para-aortic lymphadenectomy(optional) Pontential adverse risk factor:.age.positive lymphovascular invasion.tumor size Stage IB Adverse risk(-) Adverse risk(+) Brachytherapy and/or pelvic RT Brachytherapy and/or pelvic RT Brachytherapy and/or pelvic RT pelvic RT and/or vaginal.lower +chemotherapy uterine(cervical/glandular)involvement
12 Endometrial cancer 子宮內膜癌治療準則 Stage II Stage IIIA Completely surgical staging:.ath+bso.cytology.pelvic lymphadenectomy.para-aortic lymphadenectomy Stage IIIB (optional) E8 G1 G2 G3 Pelvic RT+ Pelvic RT+ and/or pelvic RT +chemotherapy Chemotherapy+RT Chemotherapy+RT Chemotherapy+RT Or tumor-directed RT+ Or tumor-directed RT+ Or tumor-directed RT+ Chemotherapy Chemotherapy Chemotherapy Or Pelvic RT+ Or Pelvic RT+ Or Pelvic RT+ Chemotherapy and/or tumor-directed RT Stage IIIC1 Pelvic node:positive Chemotherapy and/or tumor-directed RT Stage IIIC2 Para-aortic nod positive+ Pelvic node positive Chemotherapy and/or tumor-directed RT Stage IVA and B Debulking and with no gross residual disease or microscopic abdominal disease Chemotherapy+RT Stage I with positive cytology Large tumor High grade Deep myometrium Invasion LVSI Adjuvant chemotherapy
13 Endometrial cancer 子宮內膜癌治療準則 E9 Stage IA G1-2 Observe Observation or vaginal +pelvic RT Radiologic image Incomplete surgical staged Stage IA G1-2 (myometrial invasion<50%) Positive Surgical restaging or pathologic Conirmation of metastaic disease Adjuvant treatment for complete surgically staged Positive Stage IA G3 Stage IB Stage II Radiologic image Pelvic RT+ vaginal +para-aortic RT(+chemotherapy for grade 3 tumors)
14 Endometrial cancer 子宮內膜癌治療準則 E10 Stage IA (no myometrial invasion) Chemotherapy or Tumor-directed radiotherapy Biopsy: Completely surgical staging as ovarian cancer:.ath+bso Stage IA (with myometrial invasion) Stage IB Stage II Chemotherapy+Tumor-directed RT Or whole abdomen pelvic RT +vaginal.papillary serous carcinoma.cytology.clear cell carcinoma.omentectomy.carcinosarcoma.peritoneal biospy.pelvic lymphadenectomy.para-aortic lymphadenectomy.maximal tumor debulking Stage II Stage IV (adwquately debulking) Chemotherapy+Tumor-directed RT Or whole abdomen pelvic RT +vaginal Stage III or IV Chemotherapy (inadwquately debulking)
Management Algorithms for Abnormal Cervical Cytology and Colposcopy
Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationCervical Cancer 3/25/2019. Abnormal vaginal bleeding
Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationNewton Wellesley Hospital 2013
Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationAlgorithms for management of Cervical cancer
Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More information3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationGynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1
What is Gynecologic Cancer Gynecologic Cancers Marge Ramsdell RN, MN, OCN Madigan Army Medical Center Any cancer that starts in a woman s reproductive organs Each GYN cancer is unique 5 main types Cervical
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationWOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16
WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 05/01/95 ANY MISSING OR INCOMPLETE TEST RESULTS
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationCPC on Cervical Pathology
CPC on Cervical Pathology Dr. W.K. Ng Senior Medical Officer Department of Clinical Pathology Pamela Youde Nethersole Eastern Hospital Cervical Smear: High Grade SIL (CIN III) Cervical Smear: High Grade
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationNon-small cell lung cancer Guideline, version /05. Non-Small Cell Lung Cancer Clinical Practice Guideline
Non-Small Cell Lung Cancer Clinical Practice Guideline PATHOLOGIC DIAGNOSIS OF NSCLC Non-Small Cell Lung Cancer (NSCLC) INITIAL EVALUATION Pathology review H&P (include perfmance status + weight loss)
More informationJanjira Petsuksiri, M.D
GYN malignancies Janjira Petsuksiri, M.D Outlines Cervical cancer Endometrial cancer Ovarian cancer Vaginal cancer Vulva cancer 2 CA Cervix Epidemiology - Second most common female cancer Risk factors
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationECC or Margins Positive?
CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,
More information本院臨床指引乃根據 NCCN guideline 2015 V1 及 Japanese Gastric Cancer Association Guideline 2010 V3, 經多學科團隊論會共同修訂完成
前言 本院臨床指引乃根據 NCCN guideline 2015 V1 及 Japanese Cancer Association Guideline 2010 V3, 經多學科團隊論會共同修訂完成 制定人員 : 腫瘤內科 : 林育靖醫師 鄧仲仁醫師一般外科 : 吳建明醫師腸胃內科 : 梁程超醫師 林政寬醫師放射腫瘤 : 謝忱希醫師 徐晨雄醫師組織病理 : 黃文志醫師影像醫學 : 謝詔裕醫師核子醫學
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More informationRole and Techniques of Surgery in Carcinoma Cervix. Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh
Role and Techniques of Surgery in Carcinoma Cervix Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh Points for Discussion Pattern of spread Therapeutic options Types of surgical procedures
More informationManagament of Abnormal Cervical Cytology and Histology
Managament of Abnormal Cervical Cytology and Histology Ali Ayhan, M.D Başkent University Faculty of Medicine Department of Gynecology and Obstetrics Division of Gynecologic Oncology Abnormal Cytologic
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
More informationEstimated New Cancers Cases 2003
Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz Estimated New Cancers Cases 2003 Images removed due to copyright reasons.
More informationManagement and Care of Women with Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline
Management and Care of Women with Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline www.asco.org/rs-cervical-cancer-treatment-guideline Introduction
More informationHPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series
HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationCARCINOMA CERVIX. Dr. PREETHI REDDY. B. M S OBG II yr POST GRADUATE.
CARCINOMA CERVIX Dr. PREETHI REDDY. B M S OBG II yr POST GRADUATE. Introduction Cervical cancer is the second most common female malignancy worldwide. It is responsible for 4,66,000 deaths annually worldwide
More informationManagement of Abnormal Cervical Cytology and Histology
Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline
More informationCase Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationInvasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous
Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior
More informationAdjuvant treatment Tamoxifen for 5 years ER or uncertain Risk reduction for contralateral breast cancer optional AI may also be considered
共識診斷 臨床檢查 主要治療 輔助治療 術後追蹤 DCIS TisN0M0 LCIS TisN0M0 ER/PR/Her-2 ER/PR/Her-2 1. Partial mastectomy SLNB whole breast radiation therapy 2. Total mastectomy SLNB reconstruction Risk reduction surgery Adjuvant
More informationI have no financial interests to disclose.
Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data
ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital
More informationJacqui Morgan March 6, 2019
Jacqui Morgan March 6, 2019 Case 1 25yo, G2P1 Here for WWE, no problems, healthy, needs refill on OCPs. Pap- Abnormal Glandular Cells-NOS Now What?? Case 1 Colposcopy What findings? Case 1 ECC Cervical
More informationCorrelation of intermediate risk factors with prognostic factors in patients with early cervical cancer
대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationMichael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center
Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center 50 yo healthy postmenopausal female with BMI = 35 with screening PAP smear = AGUS. What is the next step? (1) Colposcopy
More informationRole of Surgery in Cervical Cancer & Research Questions
Role of Surgery in Cervical Cancer & Research Questions Arb-aroon Lertkhachonsuk, M.D., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Role of surgery in cervical cancer
More informationGynecologic Malignancies. Kristen D Starbuck 4/20/18
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
More informationThe Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD
The Role of Radiation in the Management of Gynecologic Cancers Scott Glaser, MD Nothing to disclose DISCLOSURE Outline The role of radiation in: Endometrial Cancer Adjuvant Medically inoperable Cervical
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationPRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT
PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationVaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
More informationMost common cancer Africans & Asians more prone because of poor socioeconomic condition Drastic decline in west as more detection of preinvasive
CANCER CERVIX Most common cancer Africans & Asians more prone because of poor socioeconomic condition Drastic decline in west as more detection of preinvasive leison by PAP Smears. Etiology: Age - 2 peaks
More informationARRO Case: Early-stage Endometrial Cancer
ARRO Case: Early-stage Endometrial Cancer Ankit Modh, MD (PGY-4) Faculty Advisor: Mohamed A Elshaikh, MD Department of Radiation Oncology Henry Ford Cancer Institute Case Presentation 70 y/o African American
More informationNAACCR Webinar Series /7/17
COLLECTING CANCER DATA: UTERUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationUterus Malignancies /5/15
Collecting Cancer Data: Uterus 2014-2015 NAACCR Webinar Series February 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationWhat is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2
More informationManagement that provides continuity of care for women
Management that provides continuity of care for women If women are diagnosed with reproductive tract infection, prompt treatment should be instituted according to the WHO guidelines. Though it may be preferred
More informationMRI for cervical and endometrial cancers. Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB
MRI for cervical and endometrial cancers Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB RCR 06(1) RCR 06(1) Technique Pelvic multiphased-array coil Fasting? Buscopan? ABDOMEN!!! Cx:+/- HR
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationCervical Conization. 1
Cervical Conization www.zohrehyousefi.com 1 Cone Biopsy is a surgical procedure with removal of a cone shaped portion of the cervix The extent of involvement of epithelium on the ectocervix has been clearly
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More information2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA
2009 USCAP Gyn Pathology Evening Session Case #3 Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA rzaino@psu.edu Clinical history Middle aged woman with an exophytic mass of
More informationRitu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University
Cervical Cancer Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Estimated gynecologic cancer cases United States
More informationGLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016
GLANDULAR LESIONS PITFALLS IN MANAGEMENT Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016 Introduction Cervical glandular lesions are much less common than squamous lesion Incidence
More informationUterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!
Uterine October 7, 2010 NAACCR 2010-2011 Webinar Series Session 1 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes!!! 3 NAACCR 2010-2011 Webinar
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationManagement of Cervical Cancer in Resource Limited Settings
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD MPH MS Professor, Gynecologic Oncology Icahn School of Medicine at Mount Sinai New York NY 84% of incidence and death occur in
More informationGynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0)
Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0) ** VALID ON DATE OF PRINTING ONLY all guidelines available on the Strategic Clinical Network website : GMLSC SCN Date first published
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationSession Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic
Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications Andres A. Roma, MD Cleveland Clinic No Disclosures In the past 12 months, I have not had
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationICRT รศ.พญ.เยาวล กษณ ชาญศ ลป
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationCervical Dysplasia and HPV
Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk
More informationUterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More information制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識
2006.03.09 制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識 2007.10.01 修訂 2009.04.22 修訂 2010.04.07 審閱 LCIS (Lobular Carcinoma in Situ) 2011.12.07 修訂 2012.03.07 修訂 Diagnosis Workup Risk Reduction Surveillance Biopsy
More informationThe new FIGO classification in endometrial carcinoma
The new FIGO classification in endometrial carcinoma Poster No.: C-1073 Congress: ECR 2012 Type: Educational Exhibit Authors: A. IGLESIAS CASTAÑON, M. Arias Gonzales, J. Mañas Uxó, 1 2 1 2 2 2 B. NIETO
More informationCervical Cancer Guidelines L and SC Network July Introduction:
Cervical Cancer Guidelines L and SC Network July 2018 Introduction: There was a total number of 442 cases of cervix cancer diagnosed in Lancashire and South Cumbria Cancer Network in the period 2005 2009
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationFertility-sparing surgery in young patients with cervical cancer
Fertility-sparing surgery in young patients with cervical cancer Pr Catherine Uzan Chef de service Chirurgie et cancérologie gynécologique et mammaire, Pitié Evaluation BEFORE surgery Cancer: stage, type
More information